For instance, encapsulating PD-1/PD-L1 inhibitors within PNPs can significantly increase their concentration at the tumor site, thereby enhancing immune checkpoint blockade efficacy and reducing systemic toxicity (Gao et al., 2023; Shen et al., 2021). This evidence concerns the gene CD274 and neoplasm.